PRF TECHNOLOGIES LTD (PRFX) Stock Fundamental Analysis

NASDAQ:PRFX • IL0011651580

2.96 USD
+0.05 (+1.72%)
At close: Feb 13, 2026
2.86 USD
-0.1 (-3.38%)
After Hours: 2/13/2026, 8:00:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PRFX. PRFX was compared to 191 industry peers in the Pharmaceuticals industry. PRFX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRFX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • PRFX had negative earnings in the past year.
  • In the past year PRFX has reported a negative cash flow from operations.
  • In the past 5 years PRFX always reported negative net income.
  • PRFX had a negative operating cash flow in each of the past 5 years.
PRFX Yearly Net Income VS EBIT VS OCF VS FCFPRFX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

  • The Return On Assets of PRFX (-130.69%) is worse than 83.25% of its industry peers.
  • Looking at the Return On Equity, with a value of -172.78%, PRFX is doing worse than 72.25% of the companies in the same industry.
Industry RankSector Rank
ROA -130.69%
ROE -172.78%
ROIC N/A
ROA(3y)-162.59%
ROA(5y)-109.71%
ROE(3y)-336.21%
ROE(5y)-214.62%
ROIC(3y)N/A
ROIC(5y)N/A
PRFX Yearly ROA, ROE, ROICPRFX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

  • PRFX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRFX Yearly Profit, Operating, Gross MarginsPRFX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

5

2. Health

2.1 Basic Checks

  • PRFX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PRFX has been increased compared to 5 years ago.
  • There is no outstanding debt for PRFX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRFX Yearly Shares OutstandingPRFX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
PRFX Yearly Total Debt VS Total AssetsPRFX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • PRFX has an Altman-Z score of -11.04. This is a bad value and indicates that PRFX is not financially healthy and even has some risk of bankruptcy.
  • PRFX's Altman-Z score of -11.04 is on the low side compared to the rest of the industry. PRFX is outperformed by 72.25% of its industry peers.
  • There is no outstanding debt for PRFX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.04
ROIC/WACCN/A
WACCN/A
PRFX Yearly LT Debt VS Equity VS FCFPRFX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

  • A Current Ratio of 1.59 indicates that PRFX should not have too much problems paying its short term obligations.
  • The Current ratio of PRFX (1.59) is worse than 69.63% of its industry peers.
  • PRFX has a Quick Ratio of 1.59. This is a normal value and indicates that PRFX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.59, PRFX is doing worse than 60.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.59
Quick Ratio 1.59
PRFX Yearly Current Assets VS Current LiabilitesPRFX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 81.22% over the past year.
EPS 1Y (TTM)81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, PRFX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.63% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.91%
EPS Next 2Y24.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRFX Yearly EPS VS EstimatesPRFX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2023 2024 2025 2026 -100 -200 -300 -400

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRFX. In the last year negative earnings were reported.
  • Also next year PRFX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRFX Price Earnings VS Forward Price EarningsPRFX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRFX Per share dataPRFX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

  • PRFX's earnings are expected to grow with 24.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.63%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • PRFX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

PRF TECHNOLOGIES LTD

NASDAQ:PRFX (2/13/2026, 8:00:00 PM)

After market: 2.86 -0.1 (-3.38%)

2.96

+0.05 (+1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13
Earnings (Next)N/A
Inst Owners0.42%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.31M
Revenue(TTM)N/A
Net Income(TTM)-14.59M
Analysts43.33
Price TargetN/A
Short Float %2.73%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.27
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-160.82
EYN/A
EPS(NY)-35.99
Fwd EYN/A
FCF(TTM)-7.64
FCFYN/A
OCF(TTM)-7.64
OCFYN/A
SpS0
BVpS10.82
TBVpS1.7
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -130.69%
ROE -172.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-162.59%
ROA(5y)-109.71%
ROE(3y)-336.21%
ROE(5y)-214.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.59
Quick Ratio 1.59
Altman-Z -11.04
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)63.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.15%
EPS Next Y38.91%
EPS Next 2Y24.63%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.81%
OCF growth 3YN/A
OCF growth 5YN/A

PRF TECHNOLOGIES LTD / PRFX FAQ

What is the ChartMill fundamental rating of PRF TECHNOLOGIES LTD (PRFX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PRFX.


What is the valuation status of PRF TECHNOLOGIES LTD (PRFX) stock?

ChartMill assigns a valuation rating of 1 / 10 to PRF TECHNOLOGIES LTD (PRFX). This can be considered as Overvalued.


Can you provide the profitability details for PRF TECHNOLOGIES LTD?

PRF TECHNOLOGIES LTD (PRFX) has a profitability rating of 0 / 10.


How financially healthy is PRF TECHNOLOGIES LTD?

The financial health rating of PRF TECHNOLOGIES LTD (PRFX) is 5 / 10.